胶质瘤干细胞标记物的研究进展

Research Progress of the Markers of Glioma Stem Cell

胶质瘤作为一种恶性脑肿瘤,具有预后差、易复发、对放化疗有抵抗性等特点。为了提高对胶质瘤的分级及预后评价的准确性,获得有效的、有针对性的胶质瘤干细胞(glioma stem cell,GSC)标记物具有十分重要的意义。本文主要对CD133、SSEA-1、Nestin等干细胞标记物在胶质瘤临床诊治中的应用特征与相互联系进行了综述。CD133作为一种最早发现的胶质瘤干细胞标志物应用广泛,但其分布无特异性、表达不稳定限制了其预后评价的精确性,其有效性目前仍存在争议。SSEA-1(CD15)与Nestin等分子弥补了CD133的部分不足。这三种标记物的联合应用为胶质瘤的临床诊断和治疗提供了重要的参考依据。后续研究陆续发现的A2B5、BMI1、LGR5等标记物有助于进一步了解GSC的性质,提高胶质瘤的诊治水平和预后评价的准确度。

Glioma is one kind of malignant brain neoplasm and has bad prognosis, high relapse rate and resistance to radiotherapy and chemotherapy. In order to improve the accuracy of glioma classification and prognostic evaluation, it＇s necessary to get effective and pointed glioma stem cell marker. This review mainly summarizes the applied characteristics and relationships of CD133, SSEA-1, Nestin and other stem cell markers in the glioma clinical diagnosis and treatment. CD133 has been widely applied as the earliest invented glioma stem cell marker, but now its effectiveness is controversial because it isn＇t accurate to evaluate prognosis for its non-specific distribution and unstable expression. SSEA-1（CD15） and Nestin and other molecules partly retrieve deficiency of CD133. Combined application of the three molecules provide glioma clinical diagnosis and treatment with important reference. Subsequent studies have been found markers A2 B5, BMI1 and LGR5 to further research the nature of GSC so that clinical workers maybe can improve the level of glioma clinical diagnosis and treatment and the accuracy of glioma prognostic evaluation.